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Abstract
Background: The highly pathogenic avian influenza (HPAI) virus H5N1 causes multi-organ disease and death in poultry,
resulting in significant economic losses in the poultry industry. In addition, it poses a major public health threat as it can be
transmitted directly from infected poultry to humans with very high (60%) mortality rate. Effective vaccination against HPAI
H5N1 would protect commercial poultry and would thus provide an important control measure by reducing the likelihood
of bird-to-bird and bird-to-human transmission.
Methodology/Principal Findings: In the present study we evaluated the vaccine potential of recombinant soluble trimeric
subtype 5 hemagglutinin (sH53) produced in mammalian cells. The secreted, purified sH53 was biologically active as
demonstrated by its binding to ligands in a sialic acid-dependent manner. It was shown to protect chickens, in a dose-
dependent manner, against a lethal challenge with H5N1 after a single vaccination. Protected animals did not shed
challenge virus as determined by a quantitative RT-PCR on RNA isolated from trachea and cloaca swabs. Also in mice,
vaccination with sH53 provided complete protection against challenge with HPAI H5N1.
Conclusions/Significance: Our results demonstrate that sH53 constitutes an attractive vaccine antigen for protection of
chickens and mammals against HPAI H5N1. As these recombinant soluble hemagglutinin preparations can be produced
with high yields and with relatively short lead time, they enable a rapid response to circulating and potentially pandemic
influenza viruses.
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Introduction
Influenza A viruses are enveloped, negative-strand RNA viruses
with a segmented genome. They infect a large variety of animal
species, although birds are considered to constitute the reservoir
from which all influenza A viruses in other species originate [1,2].
On the basis of the antigenic properties of their two surface
glycoproteins, hemagglutinin (HA) and neuraminidase (NA),
influenza A viruses are classified into 16 HA (H1–16) and 9 NA
(N1–9) subtypes. The highly pathogenic avian influenza (HPAI)
virus H5N1 causes multi-organ disease and death in poultry,
resulting in significant economic losses in the poultry industry.
HPAI H5N1 also poses a major public health threat as it can be
transmitted directly from infected poultry to humans with very
high (60%) mortality rate. It is widely accepted that continued
human exposure to influenza viruses circulating in wild and
domestic avian species poses a permanent pandemic threat [3,4].
Effective vaccination against HPAI H5N1 would protect com-
mercial poultry and would thus provide an important control
measure by reducing the likelihood of bird-to-bird as well as bird-
to-human transmission. Therefore, the development of efficacious
influenza vaccines is of high veterinary and public health
importance.
Conventional vaccine preparations against HPAI H5N1 are
produced by propagating virus in embryonated chicken eggs or
mammalian cells. The vaccine viruses used are either reassortants
or low pathogenic wild-type avian viruses. Either way, the viruses
need to be selected for their ability to multiply in eggs or cultured
cells, which may preclude the best genetic match to the circulating
HPAI H5N1 strains. In addition, these vaccines have several other
limitations as reviewed elsewhere [5,6]. Hence, other vaccine
strategies against HPAI H5N1 have been explored including the
use of, among others, live attenuated influenza vaccines [7,8], live
vaccines based on heterologous viral vectors such as pox virus [9],
adenovirus [10], baculovirus [11] and Newcastle disease virus
[12], and DNA vaccination [13]. While these different strategies
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often showed promising results, their applicability ultimately will
depend on various important issues including safety, efficacy,
production and costs [5].
Protective immunity against influenza virus infection and disease is
primarily conferred through HA via the induction of anti-HA
antibodies. As protection from influenza virus infection correlates
with anti-HA titers, nearly all vaccine approaches aim to induce high
levels thereof. Therefore, the HA protein is the antigen of choice for
the development of recombinant subunit vaccines to protect against
HPAI H5N1. An influenza vaccine based on recombinant purified
HA could offer the following advantages: I) The HA antigen can be
produced using safe, quality-controlled and scalable conditions. II)
There will be no need for virus cultivation, thus avoiding the necessity
a) to obtain viruses that replicate efficiently in eggs or cell culture, b) to
use biocontainment facilities and c) to inactivate the virus using
procedures that may affect antigenicity and raise safety concerns. III)
The recombinant HA protein can be highly purified thereby limiting
adverse reactions caused e.g. by the presence of egg contaminants.
IV) Immunization with recombinant HA will allow the serological
differentiation of naturally infected from vaccinated animals/flocks
(the so-called DIVA principle; [14]). IV) Recombinant HA vaccines
are manufactured with a relatively short lead time, allowing an
accelerated response to emerging influenza strains.
Recombinant HA can be produced using different expression
systems. When expressed in E. coli the resulting HA protein gave
rise to the induction of hemagglutination inhibition (HI) titers
upon immunization of mice [15]. However, as proper folding and
trimerization of the HA protein requires multiple posttranslational
modifications including glycosylation and disulfide bond forma-
tion, expression of the HA protein in higher eukaryotic systems is
likely to result in superior antigenicity. Thus, mammalian cell-
derived HA trimers were found to induce much higher levels of
neutralizing antibodies than similarly produced monomeric HA
protein [16]. The baculovirus expression system has been used to
produce strain specific HA antigens in insect cells, which were
shown to protect against a HPAI H5N1 challenge [17]. Such full-
size HA proteins may, however, be limited in their efficacy
because the membrane proteins may not retain their native
membrane-bound structure upon purification [18]. Hence, the
production of recombinant, soluble, stable HA trimers that are
secreted from the cells seems like an attractive alternative
approach. Such HA trimers, expressed either in insect or
mammalian cells, were indeed shown to elicit neutralizing
antibodies [16] and to partially protect mice against HPAI
H5N1 challenge infection [19].
In view of their promising potential we have evaluated
recombinant soluble HA trimers in chickens and mice for their
ability to induce protective immunity against infection with HPAI
H5N1. To this end, recombinant soluble H5 proteins provided
with a GCN4 trimerization motif and a STREP-tag II, the latter
for purification purposes, were expressed in mammalian cells. The
recombinant soluble H5 trimers (sH53) were purified from the
culture supernatants using a simple one-step purification protocol
and characterized with respect to their oligomeric state and
bioactivity. Subsequently, vaccination with the sH53 preparation
was shown to provide complete protection against challenge with
HPAI H5N1 both in mice and in chickens, in the latter already
after a single immunization.
Materials and Methods
Genes and expression vectors
A cDNA clone corresponding to residues 18 to 523 (H3
numbering) of the HA from A/Viet Nam/1203/2004 (H5N1)
(Genbank accession no. ABW90137.1) was synthesized using
human-preferred codons by GenScript USA Inc. In this clone the
predicted HA ectodomain protein lacks a multibasic cleavage site.
The cDNA was cloned into the pCD5 expression vector for
efficient expression in mammalian cells [20]. The pCD5 vector
had been modified such that the HA-encoding cDNA was cloned
in frame with DNA sequences coding for a signal sequence, an
artificial GCN4 isoleucine zipper trimerization motif
(KRMKQIEDKIEEIESKQKKIENEIARIKK) [21] and the
Strep-tag II (WSHPQFEK; IBA, Germany). The resulting vector
encodes the soluble trimeric H5 protein designated as sH53.
Protein expression and purification
pCD5 expression vectors containing the HA ectodomain-
encoding sequences were transfected into HEK293S GnTI(2)cells
[22] using polyethyleneimine I (PEI) in a 1:5 ratio (mg DNA: mg
PEI). At 6 h post transfection, the transfection mixture was
replaced by 293 SFM II expression medium (Invitrogen),
supplemented with sodium bicarbonate (3.7 g/liter), glucose
(2.0 g/liter), Primatone RL-UF (3.0 g/liter), penicillin
(100 units/ml), Streptomycin (100 mg/ml), glutaMAX (Gibco),
and 1,5% dimethyl sulfoxide. Tissue culture supernatants were
harvested 5–6 days post transfection. HA protein expression and
secretion was confirmed by sodium dodecylsulfate (SDS)-poly-
acrylamide gel electrophoresis (PAGE) followed by western
blotting using a mouse anti-Strep-tag antibody (IBA, Germany).
HA proteins were purified using Strep-tactin Sepharose beads
according to the manufacturer’s instructions (IBA, Germany). The
concentration of purified protein was determined by using a
Nanodrop 1000 spectrophotometer (Isogen Life Sciences) accord-
ing to the manufacturer’s instructions.
Biological characterization of recombinant HA
The oligomerization status of the sH53 proteins was determined
by analyzing the elution profile using a Superdex200GL 10–300
column (GE Healthcare). Sialic acid-binding activity of sH53 was
assessed using a fetuin solid phase assay. 1 mg/ml fetuin per well
was used to coat 96-well Nunc MaxiSorp plates. When indicated
in the figure legend, fetuin was treated with Vibrio Cholera derived
neuraminidase (VCNA; Roche) followed by three washing steps.
sH53 was pre-complexed with horseradish peroxidase (HRP)-
linked anti-Strep-tag antibody (2:1 molar ratio) for 30 min at 0uC
prior to incubation of limiting dilutions on the fetuin-coated plates
(60 min, room temperature [RT]). HA-binding was subsequently
detected using tetramethylbenzidine substrate (BioFX) in an
ELISA reader (EL-808 [BioTEK]), reading the OD at 450 nm.
Vaccination-challenge experiments in chickens
Animal studies were conducted at the Central Veterinary
Institute (CVI), Lelystad, under BSL3 conditions and after
approval by the Animal Ethic Committee. In the first chicken
experiment, 6 weeks old SPF white Leghorn chickens (Lohmann,
Cuxhaven, Germany) were used (10 chickens per group). One
group of animals was immunized twice (on day 0 and 21) by
intramuscular (i.m.) injection (0.5 ml) of 10 mg sH53 adjuvanted
with Stimune as recommended by the manufacturer [Prionics,
Lelystad]). As a challenge control, the other group received an
equal volume of PBS in Stimune (mock vaccinated). Three weeks
after the vaccination (day 42), the birds were challenged by
inoculation with 105 median tissue culture infective dose (TCID50)
of A/Viet Nam/1194/04 virus (0.1 ml intranasally [i.n.] and
0.1 ml intratracheally [i.t.]) and monitored over a period of 14
days for signs of disease. Blood samples were collected at 3 weeks
after each immunization (on day 21 and 42 post infection [p.i.]).
Recombinant Soluble HA Vaccine
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For the next experiment, 70 one-day-old layer hens (white
Leghorn) were purchased from a local breeder. The chickens had
been vaccinated against Newcastle disease virus and infectious
bronchitis virus at the age of one day according to the farm’s
routine and were raised in CVI’s animal facility. At the age of 6
weeks, the birds were transported to the BSL-3 facility and
allocated to 7 experimental groups of 10 birds each. The animals
of six groups were immunized once (on day 21) or twice (on day 0
and 21) by i.m. injection of 10, 2 or 0.4 mg sH53 antigen
adjuvanted with Stimune. When immunized twice, the same doses
were given on day 0 and 21. As a challenge control, one group was
mock-vaccinated twice (on day 0 and 21) with PBS in Stimune.
Four weeks after vaccination (day 49), blood samples were taken
and the chickens were challenged as above and observed daily for
clinical signs during 14 days. Trachea and cloaca swabs were taken
from each chicken on day 2, 4 and 7 p.i.
Vaccination-challenge experiment in mice
Female, specified pathogen-free (SPF) 9-week-old BALB/c
mice (Charles River Laboratories; 10 animals per group) were
immunized once (on day 21) or twice (on day 0 and 21) by i.m.
injection (0.2 ml) of 2 mg sH53 adjuvanted with Stimune. As a
challenge control, one group of mice was mock vaccinated.
Three weeks after the vaccination, mice were anaesthetized with
ketamin/xylazin by intraperitoneal injection and inoculated
intranasally with 50 ml of H5N1A/Viet nam/1194/04 contain-
ing ,10 median lethal dose (LD50; 3.7 10log TCID50; provided
by Dr. Alan Hay from the WHO Influenza Centre at the
National Institute for Medical Research, London). The mice
were weighed daily and examined for signs of illness during the
next 14 days. Clinical signs were recorded using a scoring
system (0 = no clinical signs; 1 = rough coat; 2 = rough coat, less
reactive, passive during handling; 3 = rough coat, rolled up,
laboured breathing, passive during handling; 4 = rough coat,
rolled up, laboured breathing, unresponsive). Animals reaching
a score of 4 were euthanized. Surviving animals were bled and
sacrificed on day 14 p.i.
Virus detection assay
Trachea and cloaca swabs were stored in cold tryptose
phosphate broth supplemented with antibiotics. The medium
was clarified by low-speed centrifugation and the supernatant was
harvested, aliquoted and stored at 270uC. Upon thawing, trachea
and cloaca swabs sampled from the same bird on the same day
were pooled and the viral RNA was extracted from 200 ml using a
MagNA Pure LC Total Nucleic Acid Isolation Kit (Roche).
Subsequently, cDNA was synthesized using reverse primer 59-
CACTGGGCACGGTGAGC-39 and part of the M1 gene was
amplified by running 45 cycles of Light Cycler PCR using primer
59-CTTCTAACCGAGGTCGAAACGTA-39 as the reverse
primer in the presence of the TaqMan fluorescent probe 59-
6FAM-TCAGGCCCCCTCAAAGCCGA-X-ph. Negative and
positive control samples were tested in parallel. The lower limit
of detection was determined to be approximately 500 TCID50.
Some samples gave inconclusive results, meaning that they gave
only a very weak signal (fluorescence,0.07) after .31 cycles.
Hemagglutination inhibition (HI) assay
Heat-inactivated immune sera from chicken blood samples were
tested for hemagglutination inhibition (HI) activity with 1%
chicken red blood cells and 4 hemagglutinating units (HAU) of
H5N1 (A/Viet Nam/1194/04 NIBRG-14). In addition, the
chicken sera were tested for HI activity using 8 HAU (67 ng) of
recombinant soluble trimeric HA protein. To this end the
recombinant proteins were precomplexed with the anti-Strep-tag
antibody as described above, mixed with limiting dilutions of the
chicken sera and incubated with 0.5% chicken red blood cells. Red
button formation was scored as evidence of hemagglutination.
Antibody titers were expressed as the reciprocal of the highest
serum dilution showing HI. Immune sera prepared from mouse
blood samples were treated with VCNA, heat-inactivated at 56uC
for 30 min and tested by HI assay using 8 HAU of sH53 as
described above.
ELISA
Total antibody titers against sH53 were determined by using a
sH53-specific ELISA. To this end, 96-well Nunc MaxiSorp plates
coated with 0.5 mg sH53 per well were incubated with limiting
dilutions of chicken or mouse sera. After extensive washing, the
plates were incubated with goat-anti-chicken or goat-anti-mouse
antibodies conjugated with HRP. Peroxidase activity was
visualized using tetramethylbenzidine substrate (BioFX) and an
ELISA reader (EL-808 [BioTEK]), reading the OD at 450 nm.
The OD values of the 250-fold diluted samples, which were in the
logarithmic phase of the curve, were plotted.
Results
Expression, purification, and characterization of sH53
In order to express soluble trimeric subtype 5 HA (sH53) in
mammalian cells, the H5 ectodomain-coding sequence was first
cloned into an appropriate expression vector. In the pCD5 vector
used, the H5-sequence was preceded by a signal peptide-encoding
sequence, to allow efficient secretion of the recombinant protein,
and followed by sequences coding for the GCN4 isoleucine-zipper
trimerizaton motif [21] and the Strep-tag II, the latter for
purification purposes (Fig. 1A). Expression of the H5 ectodomain
was achieved by transient transfection of the expression plasmid
into HEK cells. Expression and secretion of the H5 protein was
verified by subjecting cell culture supernatant to gel electropho-
resis followed by western blotting using an antibody directed
against Strep-tag II (Fig. 1B). The results show that the
recombinant H5 protein could be readily detected in the cell
culture supernatant after transfection of the cells with the
expression plasmid, but not after mock transfection. The secreted
H5 protein was purified in a single step protocol by using Strep-
tactin sepharose beads. Protein yields varied between 0.4–1 mg of
recombinant protein per 100 ml cell culture medium. After
purification of the H5 protein from the cell culture supernatant,
the oligomeric state of the H5 protein was analyzed by gel
filtration column chromatography (Fig. 1C). The bulk of the H5
protein eluted with the velocity of an oligomer, while only a minor
fraction was found as aggregates in the void volume. The trimeric
nature of the H5 oligomer was confirmed using blue-native gel
electrophoresis followed by western blotting (Fig. 1D). When the
H5 preparation was heat-denatured for increasing time periods
prior to electrophoresis, the initially trimeric HA species
dissociated into dimers and monomers. The biological activity of
the purified sH53 was studied using a solid phase-binding assay
with the sialylated blood glycoprotein fetuin. Binding of sH53 was
measured by means of the HRP conjugated to the anti-Strep-tag II
antibody as detailed in the Material and Methods section. The H5
preparation exhibited a concentration dependent binding to the
fetuin. This binding was sialic acid-dependent, as no binding was
observed when the fetuin had been treated with neuraminidase
(VCNA; Fig. 1E). In conclusion, biologically active sH53 was
efficiently produced using a mammalian expression system and
readily purified.
Recombinant Soluble HA Vaccine
PLoS ONE | www.plosone.org 3 May 2010 | Volume 5 | Issue 5 | e10645
Efficacy of sH53 as a vaccine against lethal HPAI H5N1
infection in chickens
To examine the immunogenicity of sH53 and its potential as a
vaccine a first experiment in chickens was performed, in which 10
chickens were vaccinated twice (on day 0 and 21) i.m. with 10 mg of
Stimune-adjuvanted sH53 and challenged 3 weeks later by i.n./i.t.
inoculation of a lethal dose of A/Viet Nam/1194/04 virus. Another
10 birds were mock-vaccinated to serve as challenge controls. As
shown in Fig. 2, the boost vaccination with 10 mg sH53 conferred
complete protection. None of the vaccinated chickens died or showed
symptoms indicative of influenza-related disease, whereas all mock-
vaccinated chickens succumbed within 2 days. Serological analysis
showed that none of the mock-vaccinated animals contained
antibodies against sH53 as determined by a sH53-specific ELISA
(Fig. 2B). In contrast, all immunized animals demonstrated
appreciable levels of HA antibodies already after a single immuni-
zation and these levels increased further after the boost. These total
antibody levels against sH53 correlated nicely with the HI titers
against H5N1 (Fig. 2C). All mock-vaccinated chickens had a HI titer
below the detection limit. HI antibody titers observed after the sH53
boost reached with a maximum of 1024 and a minimum of 64, which
was apparently still sufficient to protect the animal against the lethal
challenge. Interestingly, 50% of the birds developed HI antibody
titers equal to 64 or higher already three weeks after the first
vaccination. In addition, HI titers were also determined by using
sH53 rather than H5N1 virus as the hemagglutinating agent, which
gave essentially similar results (compare Fig. 2D and 2C),
demonstrating the reliability of the assay. In summary, the results
show that chickens vaccinated twice with sH53 are protected against a
lethal challenge with H5N1. The HI titers observed suggested that
one vaccination might already be sufficient to confer protection
against HPAI H5N1.
Vaccination efficacy in chickens: effect of antigen dose
and vaccination booster
These results prompted us to determine the minimal sH53 dose
required to confer protection and to examine whether a single dose
could already be sufficient. In the second vaccination-challenge
experiment, chickens were thus vaccinated with 10, 2 or 0.4 mg of
sH53 either once or twice and challenged four weeks later by infection
with a lethal dose of A/Viet Nam/1194/04 as described above. The
results are shown in Fig. 3. Again, all mock-vaccinated birds
succumbed to the infection within 2 days. Vaccinating twice with a
dose of 0.4 mg of sH53 was sufficient to protect 90% of the chickens
Figure 1. Expression, purification and biological activity of recombinant, soluble trimeric H5 protein. (A) Schematic representation of
the H5 expression cassettes used. The H5 ectodomain encoding sequence (H5) was cloned in frame with DNA sequences coding for a signal peptide
(SP), the GCN4 isoleucine zipper trimerization motif (GCN4) and the Strep-tag II (ST) under the control of a CMV promoter. (B) H5 expression and
secretion into the culture media was analyzed by SDS-PAGE followed by western blotting. The recombinant protein was detected using a mouse anti-
Strep-tag antibody. (C) Analysis of purified recombinant H5 proteins by gel filtration. Shown is the elution profile of a H5 protein preparation using a
Superdex200GL 10–300 column. The elution of a 232 kDa catalase control is indicated by the line. (D) Blue native-PAGE analysis of the recombinant
H5 protein. The position in the gel of the momomeric, dimeric and trimeric ectodomain species observed after heating of the HA sample prior to
electrophoresis is indicated. (E) Recombinant soluble H5 trimers were complexed with a HRP-conjugated mouse antibody directed against the Strep-
tag prior to their application in a fetuin binding assay. HA binding was also assessed after treatment of fetuin with VCNA (fetuin+VCNA).
doi:10.1371/journal.pone.0010645.g001
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against mortality, while all chickens survived when a dose of 2 or
10 mg was similarly administered (Fig. 3A). Interestingly, also single
vaccination with sH53 could induce sufficient immunity to protect
chickens against lethal infection (Fig. 3B); when a dose of 2 mg was
given only one chicken died (90% protection), whereas a dose of
10 mg was protective to all birds. Even after a single dose of 0.4 mg,
60% of the chickens were protected against death.
Serological analysis showed that protection against the lethal
H5N1 challenge correlated well with the observed antibody levels
against sH53 as determined by ELISA (Fig. 3C–D) and by HI assay
(Fig. 3E–F). Both assays revealed a dose-dependent antibody
response, which was substantially enhanced after the booster
immunization. Relatively high HA antibody levels were observed
after two immunizations, even with the lower dose, except in two
animals, one of which did not survive the challenge (Fig. 3C). Also
after a single immunization, significant antibody levels were
measured, except again in the low dose group. Here, 5 animals
had hardly measurable ELISA titers. Consistently, 4 of these animals
succumbed to the challenge. Also the one animal that died after a
single immunization with 2 mg of sH53 did not have detectable sH53
antibodies. Essentially the same results as with the ELISA were
obtained with the HI assay using sH53 as the hemagglutinating agent
(Fig. 3E–F). Thus, the animals that succumbed to the lethal challenge
after a single immunization also exhibited the lowest HI titers.
Shedding of challenge virus from vaccinated chickens
We analyzed whether vaccination with sH53 decreased or
prevented chickens from shedding challenge virus. For practical
reasons, virus shedding was analyzed by a quantitative RT PCR
rather than by measuring infectious virus titers. To this end,
trachea and cloaca swabs were taken from the chickens of the
vaccine dose titration experiment of Fig. 3 at 2, 4 and 7 days after
the challenge inoculation. The tracheal and the cloacal swab
sampled from each chicken at each particular day were pooled and
the presence of viral RNA in the pooled swabs was analyzed using
a quantitative RT PCR assay detecting the M1 gene. The results
are shown in Table 1. Of the chickens that received a booster
vaccination, only 2 birds, both of which had received the lowest
amount of antigen, tested positive. Notably, these were the two
animals that developed the lowest sH53-specific antibody titers
(Fig. 3C). One of these animals did not survive the challenge. Virus
shedding could not be detected in any of the other birds, although
3 swabs gave inconclusive results. Of the chickens vaccinated only
once, all animals that died tested positive. None of the birds
vaccinated with 10 mg sH53 tested positive. Of the chickens
vaccinated with a lower dose and surviving, two tested positive, but
only at day 2 p.i. In conclusion, the vaccinated birds that could
control the lethal HPAI H5N1 challenge infection exhibited
minimum or no virus shedding.
Efficacy of sH53 vaccine against a lethal HPAI H5N1
infection in mice
Finally we examined whether sH53 would also confer protection
in mice. Therefore, 2 groups of 10 mice were vaccinated either
once (on day 21) or twice (on day 0 and 21) with 2 mg of sH53
adjuvanted with Stimune and challenged three weeks later by
Figure 2. sH53 vaccination in chickens. Ten chickens were immunized two times with 10 ug sH53 (on day 0 and 21). As a challenge control,
chickens were mock-treated (PBS). Three weeks after the vaccination, all birds were challenged with 105 TCID50 of HPAI H5N1 A/Viet Nam/1194/04 (A)
Kaplan-Meier survival curves, indicating percentage mortality on each day for each group (B–C–D) Blood samples were collected 3 weeks after the
first immunization (sH53 16) and 3 weeks after the second vaccination (sH53 26). The sH53 antibody levels as determined by ELISA (B), the HI titers
against H5N1 (NIBRG-14) (C) and the HI titers against sH53 (D) in serum for each bird. Bars represent geometric means per group. The dotted lines
indicate the lowest antibody levels correlating with protection in this experiment.
doi:10.1371/journal.pone.0010645.g002
Recombinant Soluble HA Vaccine
PLoS ONE | www.plosone.org 5 May 2010 | Volume 5 | Issue 5 | e10645
intranasal inoculation with ,10 LD50 of H5N1 A/Viet Nam/
1194/04. The percentage of mice surviving the infection, median
clinical scores and body weights per group observed after the
challenge inoculation are shown in Fig. 4. All mock-vaccinated
mice succumbed to infection or had to be euthanized by day 9 p.i..
These mice showed severe clinical signs, including respiratory
distress and significant weight loss, which continued until the
animals died. A booster vaccination with sH53 provided 100%
protection against the lethal dose of A/Viet Nam/1194/04; none
of the mice showed significant signs of disease and their body
weights remained constant. A single vaccination with sH53 did not
protect mice against disease and concurrent weight loss; yet 40%
of the mice survived. These mice started to recover from day 9 p.i.
onwards as demonstrated by their regain of body weight. (Fig. 4C).
Fig. 4D shows the pre-challenge anti-sH53 antibody levels in
individual serum samples,as determined by ELISA. Such anti-
bodies could be detected in most vaccinated animals. However,
after a single immunization, these levels remained very low
compared to those in animals that received a booster vaccination.
These results were essentially confirmed by determining the HI
titers against sH53 in the same serum samples. With the exception
of one animal, the serum of which demonstrated high levels of
auto-agglutination, all mice displayed high HI titers when
vaccinated twice and low HI titers when vaccinated once. Thus,
mice vaccinated twice with sH53 were protected against a lethal
challenge with HPAI H5N1, while a single vaccination provided
partial protection. The differences in protection correlated with
the observed serum HI titers.
Discussion
Despite all the-understandable-attention drawn in the past year by
media and scientific community to the new pandemic influenza A
virus H1N1, a large influenza threat continues to be posed by HPAI
H5N1. In 2009, HPAI H5N1 was found in wild birds in Germany,
China, Mongolia and the Russion Federation, several outbreaks of
the virus in poultry were reported in Viet Nam, Hong Kong, Nepal,
India, Bangladesh, Egypt, Lao DPR, and Cambodia, while H5N1
remained endemic in large areas of Indonesia. That same year also
dozens of confirmed human cases were reported (WHO timeline of
major events; http://www.who.int/csr/disease/avian_influenza/
ai_timeline/en/index.html). Even though the virus has so far
Figure 3. sH53 dose titration after a single or boost vaccination in chickens. Seven groups of 10 chickens were immunized i.m. with 10, 2 or
0.4 mg sH53 either once or twice with 3 weeks interval. As a challenge control, one group was mock-treated (PBS). Four weeks after the vaccination, all
chickens were challenged with 105 TCID50 of HPAI H5N1 A/Viet Nam/1194/04. Kaplan-Meier survival curves, indicating percentage mortality on each
day for each group that was (mock-)vaccinated twice (A) or once (B). (C–D) The sH53 antibody levels at the day of challenge as determined by ELISA
for each chicken that was (mock-)vaccinated twice (C) or once (D). (E–F) Serum HI titers in the same sera, measured against sH53 for the chickens that
were (mock-)vaccinated twice (E) or once (F). Bars represent the geometric means for the test groups.
doi:10.1371/journal.pone.0010645.g003
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remained restricted in its ability to infect humans and initiate efficient
human-to-human transmission, its persistence and spread among
wild birds and poultry holds a continual risk of the emergence of a
pandemic strain. This threat can be reduced by vaccination of poultry
against H5N1 as this would limit the propagation of the virus and
minimize the risk of bird-to-human transmission. In addition, in case
a human pandemic H5N1strain would emerge, there would be an
immediate need for effective and reliable vaccines matching the
pandemic strain. In the present study we evaluated the vaccine
potential of a recombinant soluble H5 protein (sH53) to protect
chickens and mice against a lethal infection with HPAI H5N1. The
recombinant HA vaccine, which has a short development cycle,
proved to be protective after a single immunization in its natural host,
while a booster vaccination was needed to confer complete protection
in a mammalian model. In addition, the sH53 induced immunity
prevented viral shedding from chickens. These promising results
warrant further research into the development of recombinant
soluble HA as a fast, safe and effective alternative vaccine not only
against H5N1, but against other influenza A viruses as well.
The recombinant HA expression cassette was constructed such
that the HA protein was produced and secreted by cells in high
yields as a bioactive trimer. The importance of the oligomeric state
of the HA protein for the induction of neutralizing antibodies has
recently been demonstrated [16]. High-molecular-weight oligo-
mers and trimers, but not monomers, were found to efficiently
induce neutralizing antibodies in mice. This difference was
attributed to the preferential induction of antibodies against
epitopes present in the monomeric, but not in the trimeric form
[16]. While the soluble recombinant HA trimers were purified
using metal affinity chromatography followed by ion-exchange
chromatography in previous studies [16,19], we used a protocol
based on the Strep-tag system [23]. Proteins with a Strep-tag
exhibit high affinity towards Strep-tactin, an engineered form of
streptavidin. By exploiting this highly specific interaction, Strep-
tagged proteins can be isolated in one step. Furthermore, because
the Strep-tag elutes under gentle, physiological conditions it is
especially suited for the generation of native proteins [24], a
characteristic that in the case of HA may contribute to the ability
of the recombinant protein to induce neutralizing antibodies.
The efficacy of the sH53 vaccine was first studied in chickens.
Adjuvanted with Stimune, a water-in-oil adjuvant also known as
Specol, the sH53 protein formulation induced an immunity that
was completely protective against a lethal H5N1 challenge after
administration of two doses ($2 mg sH53/dose). Importantly, our
vaccine preparation also protected chickens after a single
immunization. While 100% of the chickens were protected after
vaccination with 10 mg sH53, 90% were protected when using
2 mg. Similar HA doses were previously needed to protect chickens
with a vaccine preparation consisting of full length HA proteins,
which had been purified from insect cell cultures infected with
recombinant baculovirus expressing the H5 gene, emulsified in a
water-in-oil adjuvant [17]. These results are consistent with the
observation that mammalian cell-produced HA trimers elicited
similar levels of neutralizing antibodies as trimeric HA produced
in insect cells [16]. The efficacy of our sH53 vaccine preparation
was furthermore demonstrated by the absence of viral RNA in the
protected birds. This would imply that a vaccinated flock can pose
a barrier against further spread of circulating virus.
Most conventional influenza vaccines require two vaccination
rounds to produce antibody titers sufficiently high to confer full
protection to chickens. In this regard, vaccination with sHA3
provides potential advantages over other vaccine approaches.
However, the production costs per dose of sHA3 compared to
egg-cultured inactivated whole-virus vaccines might be higher,
even though recombinant protein expression in mammalian cell
culture systems has been shown to be highly scalable and
productive, with expression levels up to the order of grams of
protein per liter [25,26]. sHA3 vaccination could however be
economically feasible in epidemic situations when millions of
chickens have to be vaccinated individually, provided that a
single preventive vaccination would suffice. Moreover, vaccinated
flocks housed in endangered regions rapidly achieve a state of
protective immunity. This may be a particularly valuable feature
in the event of a pandemic, when the virus transmission cycle
needs to be interrupted as soon as possible and the risk of
exposure of farmers, veterinarians and people in monitoring
teams to potentially zoonotic HPAI should be limited to the
upmost extent.
Table 1. Virus detection in tracheal and cloacal swabs collected from vaccinated chickens after challenge with H5N1.
1x vaccinationa 2x vaccination
10 2 0.4 10 2 0.4 0
Chicken # D2 D4 D7 D2 D4 D7 D2 D4 D7 D2 D4 D7 D2 D4 D7 D2 D4 D7 D2
1 2b 2 2 + + 6{ 2 2 2 2 2 2 2 2 2 2 2 2 +{
2 2 2 2 2 2 2 + + +{ 2 2 6 2 2 2 2 + +{ +{
3 2 2 2 2 2 2 + 2 2 2 2 2 6 2 2 2 2 2 +{
4 2 2 2 + 2 2 + x{ x{ 2 2 2 2 2 2 2 2 2 +{
5 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 +{
6 6 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 +{
7 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 + + 2 +{
8 6 2 2 2 2 2 6 2 2 2 2 2 2 2 2 2 2 2 +{
9 2 2 2 2 6 2 + + +{ 2 2 2 2 2 2 2 2 2 +{
10 2 2 2 2 2 2 + x{ x{ 2 2 2 2 6 2 2 2 2 +{
aAmount of sH53 per immunization dose is indicated in mg. Day post infection (D) on which the tracheal and cloacal swabs were collected are indicated.
b+=positive; 6= inconclusive (low fluorescence [,0.07] after more than 31 cycles); 2=negative; x = not tested.
{= chicken did not survive the challenge with HPAI H5N1.
doi:10.1371/journal.pone.0010645.t001
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The efficacy of the sH53 vaccine was also studied in mice. The
vaccine preparation was completely protective against a lethal
H5N1 challenge after 2 doses. Immunization with a single dose
resulted in 40% survival. These differences in protection levels
correlated with the observed anti-sH53 titers in the animals’ sera.
As the dose (2 mg) received by the mice is at least comparable,
relative to their body weights, to the dose that conferred complete
protection in chickens after a single immunization (10 mg), these
results appear to suggest that the sH53 is more effective in
conferring a protective immune response in chickens than in mice.
The reason for this apparent discrepancy is unclear and warrants
further investigations. In the only other study so far that used
soluble HA trimers as a vaccine preparation in mice, much less
protection against challenge with H5N1 was observed after two
immunizations [19]. Although the H5 trimer produced in this
latter study differed from the one that we used, with respect to the
trimerization motif (t4 foldon vs GCN4 trimerization motif) and
the purification tag (His tag vs Strep tag II), the difference is more
Figure 4. sH53 vaccination of mice. Groups of 10 BALB/c mice were immunized i.m. with 2 mg sH53 either once (day 21) or twice with a 3-week
interval (day 0 and day 21). As a challenge control, one group of mice was mock-treated (PBS) twice (day 0 and day 21). Three weeks after the
vaccination, mice were infected with ,10 LD50 of A/Viet Nam/1194/04 and monitored daily for clinical signs and body weight during the next 14
days. (A) Kaplan-Meier survival curve indicating percentage mortality on each day for each group. (B) Median clinical scores per group. (C) Mean body
weights per group expressed as percentage of starting body weight, plotted as a function of time. Error bars represent the standard deviation. (D–E)
Blood samples were collected at the day of challenge. sH53 antibody levels as determined by ELISA (D). HI titers against sH53 (E). Bars represent
geometric means.
doi:10.1371/journal.pone.0010645.g004
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likely to be explained by the different adjuvant used (Alum vs
Stimune). Alum is known to induce low antibody titers when used
with subunit vaccines [27], while Stimune has been reported to
generate long-lasting, functional antibody responses [28,29,30].
Stimune is however not licensed for human use.
In conclusion, we have shown that the sH53 protein produced in
mammalian cells elicited protective immune responses in mice and
chickens when adjuvanted with Stimune. Chickens protected
against the lethal H5N1 challenge also did not shed the virus at
day 7 post infection. As these recombinant HA vaccines can be
manufactured with high yields and a relatively short lead time,
they offer an attractive alternative vaccination strategy, which will
allow a rapid response to circulating and potentially pandemic
influenza viruses.
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